Dose-intensive vinorelbine with concurrent granulocyte colony- stimulating factor support in paclitaxel-refractory metastatic breast cancer

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1395-1400

  Livingston, R B ^a   Ellis, G K ^a   Gralow, J R ^a   Williams, M A ^a   White, R ^a   McGuirt, C ^a   Adamkiewicz, B B ^a   Long, C A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; HUMAN TISSUE; ILEUS; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031002744     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1395     Document Type: Article

References (21)

1. Fellous A, Ohayon R, Vacassin T, et al: Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16:9-14, 1989 (suppl 4)
2. Weber BL, Vogel C, Jones S, et al: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730, 1995
3. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567-2574, 1995
4. Fraschini G, Yap H-Y, Hortobagyi GN: Five-day continuous-infusion vinblastine in the treatment of breast cancer Cancer 56:225-229, 1985
5. Tannock I, Erlichman C, Perrault D, et al: Failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory breast cancer. Cancer Treat Rep 66:1783-1784, 1982
6. Ingle JN, Ahmann DL, Gerstner JG, et al: Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer. Cancer Treat Rep 68:803-804, 1984
7. Yap H-Y, Blumenschein GR, Bodey GP, et al: Vindesine in the treatment of refractory breast cancer: Improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep 65:775-779, 1981
8. Yau JC, Yap H-Y, Buzdar AU, et al: A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer 55:337-340, 1985
9. Toussaint C, Izzo J, Spielmann M, et al: Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 12:2102-2112, 1994
10. Ellis GK, Livingston RB: Augmented dose intensity with concurrent G-CSF and continuous 5FU, Adriamycin and cyclophosphamide chemotherapy for breast cancer. Proc Am Soc Clin Oncol 13:58, 1994 (abstr 35)
11. Gasparini G, Caffo O, Barni S, et al: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 12:2094-2101, 1994
12. Marty M, Leandri S, Extra J, et al: A phase II study of vinorelbine in patients with advanced breast cancer. Proc Am Assoc Cancer Res 30:256, 1989 (abstr 1017)
13. Bezwoda WR, Seymour L, Ariad S: High-dose etoposide in metastatic breast cancer. Oncology 49:104-107, 1992
14. Holmes FA, Valero V, Theriault RL, et al: Phase II trial of Taxol in metastatic breast cancer refractory to multiple prior treatments. Proc Am Soc Clin Oncol 12:94, 1993 (abstr 178)
15. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13:2056-2065, 1995
16. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
17. Brambilla C, Zambetti M, Ferrari L, et al: Mitomycin C and vinblastine in advanced refractory breast cancer. Tumori 75:141-144, 1989
18. Seidman AD, Hochhauser D, Yao T-J, et al: 96 Hour Taxol after prior short taxane infusion: Phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Proc Am Soc Clin Oncol 14:113, 1995 (abstr 151)
19. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565, 1980
20. Cabral F, Wible L, Brenner S, et al: Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 97:30-39, 1983
21. Zhan Z, Kang Y-K, Giannakakou P, et al: Tubulin expression and polymerization in normal tissues, human tumors and paclitaxel selected ovarian and breast cancer carcinoma cell lines. Proc Am Assoc Cancer Res 35:390, 1994 (abstr 2326)